Mirum Pharmaceuticals Aktie
WKN DE: A2PM29 / ISIN: US6047491013
18.12.2023 15:30:07
|
Mirum Pharma Says EMBARK Phase 2b Study Evaluating LIVMARLI Fails To Meet Endpoints
(RTTNews) - Mirum Pharmaceuticals, Inc. (MIRM) announced Monday top-line results of the Phase 2 EMBARK study evaluating LIVMARLI (maralixibat) oral solution versus placebo given as an adjuvant therapy to Kasai surgery in patients with biliary atresia.
The study did not meet its primary endpoint of mean change in bilirubin from baseline to Week 26, or the key secondary endpoints. Baseline characteristics were well-balanced between the groups. LIVMARLI was generally well-tolerated, with no new safety findings.
The Phase 2b EMBARK study is a randomized, double-blind, placebo-controlled clinical trial evaluating the safety and efficacy of LIVMARLI (maralixibat) oral solution in patients with biliary atresia who have undergone a Kasai surgery.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Invmehr Nachrichten
05.08.25 |
Ausblick: Mirum Pharmaceuticals stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
06.05.25 |
Ausblick: Mirum Pharmaceuticals verkündet Quartalsergebnis zum jüngsten Jahresviertel (finanzen.net) |